Medical

Home>Medical
Oct 4 2023

Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)

By |2023-10-03T20:16:16-04:00October 4th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase ...

Sep 20 2023

Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts

By |2023-09-19T19:50:39-04:00September 20th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA September 20, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI).  The initial focus will be on accelerating and fine-tuning Halberd’s proprietary nasal spray for suppressing ...

Sep 6 2023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

By |2023-09-06T05:46:15-04:00September 6th, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate ...

May 2 2023

Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

By |2023-05-01T20:26:07-04:00May 2nd, 2023|Investor News, Medical, News, Press Releases|0 Comments

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray.  The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma.  The focus of ...

Apr 3 2023

Halberd’s Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens

By |2023-04-03T05:07:20-04:00April 3rd, 2023|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, April 3, 2023 – Halberd Corporation (OTC PINK:HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd’s incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC. Halberd participants ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By |2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC.  Using Halberd’s patented extracorporeal ...

Mar 14 2023

Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens

By |2023-03-14T05:42:44-04:00March 14th, 2023|Featured, Investor News, Medical, Press Releases|0 Comments

Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli ...

Feb 21 2023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-21T05:34:56-05:00February 21st, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes.  Halberd’s patented extracorporeal process and patent-pending ...

Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By |2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples.  Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Go to Top